Titan Biotech Limited , a key player in the biotechnology sector, has announced strong financial results for the second quarter ended September 30, 2025, showcasing significant growth in both revenue and profitability.

Financial Highlights

The company reported a substantial increase in its revenue from operations, which stood at Rs. 5,679.20 lakhs for Q2 FY2026, compared to Rs. 4,721.86 lakhs in the previous quarter, marking a robust growth of 20.27%. This impressive top-line performance underscores Titan Biotech's strong market position and growing demand for its products.

Profitability also saw a notable improvement, with net profit for the quarter reaching Rs. 686.25 lakhs, up from Rs. 616.08 lakhs in the prior quarter, representing an 11.39% increase. This growth in profitability reflects the company's effective cost management and operational efficiency.

Half-Yearly Performance

For the six-month period ending September 30, 2025, Titan Biotech's revenue reached Rs. 10,401.06 lakhs, compared to Rs. 9,715.64 lakhs in the same period last year, indicating a year-on-year growth of 7.05%. This consistent performance over the first half of the fiscal year demonstrates the company's resilience and ability to maintain growth momentum.

Earnings Per Share

The company's earnings per share (EPS) for Q2 FY2026 stood at Rs. 8.30, a significant increase from Rs. 7.46 in the previous quarter. This 11.26% growth in EPS is likely to be well-received by investors, as it indicates improved returns on their investments.

Management Approval

The Board of Directors of Titan Biotech Limited approved both standalone and consolidated unaudited financial results at their meeting held on November 11, 2025. This approval underscores the management's confidence in the company's financial performance and reporting standards.

Consolidated Performance

On a consolidated basis, Titan Biotech Limited, along with its associates Peptech Biosciences Limited and Titan Media Limited, demonstrated strong financial results. The consolidated revenue from operations for Q2 FY2026 was Rs. 5,435.47 lakhs, with a total income of Rs. 5,567.92 lakhs.

The consolidated profit before tax for the quarter stood at Rs. 921.86 lakhs, while the profit after tax reached Rs. 776.47 lakhs, including the share of profit from associates.

Balance Sheet Strength

As of September 30, 2025, Titan Biotech's consolidated balance sheet showed total assets of Rs. 20,248.60 lakhs, up from Rs. 17,470.75 lakhs as of March 31, 2025. The company's equity position remained strong, with total equity increasing to Rs. 16,641.45 lakhs from Rs. 15,340.32 lakhs at the end of the previous fiscal year.

Cash Flow and Liquidity

The company maintained a healthy cash position, with cash and cash equivalents of Rs. 163.27 lakhs as of September 30, 2025. The net cash generated from operating activities for the six-month period was robust, indicating strong operational cash flows.

Conclusion

Titan Biotech Limited's Q2 FY2026 results reflect a company on a strong growth trajectory, with impressive revenue growth, improved profitability, and a solid balance sheet. The consistent performance across both standalone and consolidated figures suggests that the company's core operations and its associates are contributing positively to its overall financial health.

Titan Biotech Limited , a leading biotechnology company, has announced its unaudited financial results for the first quarter ended June 30, 2025, along with significant board-level changes and dividend plans.

Financial Performance

The company reported a robust performance in Q1 FY2026:

• Standalone revenue increased by 7.8% to Rs. 46.50 crore, up from Rs. 43.11 crore in the same quarter last year.
• Net profit saw a notable rise of 8.1%, reaching Rs. 6.16 crore compared to Rs. 5.70 crore year-over-year.
• Earnings per share (EPS) improved to Rs. 7.46 from Rs. 6.90 in the previous quarter.

Board Appointments and Re-appointments

Titan Biotech has made several key changes to its board:

1. New Independent Director: Mr. Debendra Kumar Sabat has been appointed as an Additional Independent Director, effective August 13, 2025. Mr. Sabat brings over 20 years of legal expertise, with experience in finance, taxation, and corporate law.

2. Re-appointment of Managing Directors:

   • Mr. Naresh Kumar Singla has been re-appointed as Managing Director for a five-year term from April 1, 2026, to March 31, 2031.
   • Mr. Suresh Chand Singla has also been re-appointed as Managing Director for the same period.

Both re-appointments are subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Dividend Announcement

The Board of Directors has recommended a final dividend of Rs. 2.00 per share for the financial year ended March 31, 2025. The record date for dividend eligibility is set for September 19, 2025.

Annual General Meeting

Titan Biotech has scheduled its 33rd Annual General Meeting for September 26, 2025, to be held via video conferencing. Key dates include:

• AGM Date: September 26, 2025
• Record Date for Dividend: September 19, 2025
• Book Closure: September 21-26, 2025 (both days inclusive)

E-Voting Details

For shareholder convenience, the company has provided e-voting facilities:

• E-voting Cut-off Date: September 19, 2025
• Remote E-voting Period: September 22, 2025 (10:00 AM) to September 25, 2025 (5:00 PM)

Titan Biotech's strong Q1 performance, coupled with strategic board changes and shareholder-friendly initiatives, positions the company for continued growth in the biotechnology sector. Investors and stakeholders will be keenly watching the company's future developments and the outcome of the upcoming AGM.